Skip Navigation LinksHome > April 2010 - Volume 32 - Issue 2 > The Benefit of Simplification From Tipranavir/Ritonavir 500/...
Text sizing:
A
A
A
Therapeutic Drug Monitoring:
doi: 10.1097/FTD.0b013e3181d3f97f
Short Communication

The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring

Morello, Judit PharmD*; Rodríguez-Novoa, Sonia PhD*; Blanco, Francisco PhD*; Vispo, Eugenia PhD†; Barreiro, Pablo PhD†; Gonzalez-Pardo, Gema*; Jiménez-Nácher, Inmaculada PhD*; González-Lahoz, Juan PhD†; Soriano, Vincent PhD†

Collapse Box

Abstract

Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although all patients on TVP/RTV 500/200 remained stable for the next 12 weeks, 3 out of 5 patients who switched doses experienced benefits in terms of reducing aminotransferases and total cholesterol. Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.